RxDoctor Payments Data

Muhammad Al Sharif, DO

Cardiovascular Disease · Springfield, MONPI 1558367284

Payments from drug & device makers

$2,090in general payments, 2019–2025

Across 109 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$699
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$622
  • Novartis$257
  • E.r. Squibb & Sons, L.L.C.$137
  • Johnson & Johnson$82
  • Boston Scientific$73
  • plus $221 from 9 others

What the payments were for

  • Food & beverage$1,61377%
  • Education$46222%
  • Gifts$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,090 in reported general payments places this provider in the 45th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$105,784
Medicare patients
1,150
Services billed
1,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$164,249
XareltoRivaroxaban27$31,405
EntrestoSacubitril/Valsartan18$22,348
BrilintaTicagrelor20$18,091
JardianceEmpagliflozin15$15,778
FarxigaDapagliflozin Propanediol16$14,113
Repatha SureclickEvolocumab19$12,571
Metoprolol Succinate328$4,364
VascepaIcosapent Ethyl12$3,112
Atorvastatin Calcium271$2,206
Dofetilide18$1,918
Losartan Potassium190$1,392
Potassium Chloride36$1,357
Spironolactone-HctzSpironolact/Hydrochlorothiazid23$1,154
ClopidogrelClopidogrel Bisulfate130$1,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$164,249186 claims
AstraZenecaBrilinta, Farxiga$699$32,20436 claims
Johnson & JohnsonXarelto$82$31,40527 claims
NovartisEntresto$257$22,34818 claims
Boehringer IngelheimJardiance$28$15,77815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →